Be The Match BioTherapies now offers cryopreserved cord blood units (CBU) as allogeneic cell therapy starting material.
Potential applications of the CBUs include non-clinical, clinical and commercial use.
The company’s registry has more than 266,000 fully-characterized CBUs from domestic cord blood banks.
Be The Patch offers comprehensive characterization information about CBUs to identify therapy-matched units.
Donna Regan, senior director, customer Ready Products at NMDP/Be The Match, said in a news release that the company ensures that the CBUs conform to specific temperature and time guidelines.
The company touts its ability to serve as a single point of contact for CBUs, eliminating the need to qualify and contract with multiple cord blood banks across the country.
Be The Match BioTherapies’ registry includes more than 9 million potential blood stem cell donors in the U.S. Additionally, the company has access to as many as 39 million potential donors internationally.
Be the Match BioTherapies also provides follow-up tracking for the first two FDA-approved CAR-T therapies.
The company has forged or expanded several alliances in recent years.
In October 2020, the company expanded a collaboration with Gamida Cell (Nasdaq:GMDA) related to omidubicel, Gamida Cell’s cell therapy in Phase 3 clinical trials.
It announced a partnership with Lonza in late 2020 related to the cell and gene therapy supply chain.
In late 2021, Be The Match BioTherapies entered into a partnership with Vineti, which has developed a platform for cell and gene therapy supply chains.
Early this year, Be The Match BioTherapies announced that it had extended a collaboration with Atara Biotherapeutics (Nasdaq:ATRA) to offer healthy donor cells for Atara’s off-the-shelf T-cell immunotherapy platform for cancer and autoimmune disease patients.
The company also has a research partnership with the Center for International Blood and Marrow Transplant Research (CIBMTR).
Be The Match BioTherapies is a division of the National Marrow Donor Program/Be The Match.
Filed Under: Cell & gene therapy
